Artiva Biotherapeutics

company

About

Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$78M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2019
Number Of Employee
11 - 50
Operating Status
Active

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$78M
Artiva Biotherapeutics has raised a total of $78M in funding over 2 rounds. Their latest funding was raised on Jun 26, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 26, 2020 Series A $78M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Artiva Biotherapeutics is funded by 1 investors. Medivate Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Medivate Partners Series A